Onconova Therapeutics, Inc. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Onconova Therapeutics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Onconova Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Onconova Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Onconova Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Onconova Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Onconova Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Onconova Therapeutics, Inc.'s pipeline products

Reasons to buy

- Evaluate Onconova Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Onconova Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Onconova Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Onconova Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Onconova Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Onconova Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Onconova Therapeutics, Inc. Snapshot 5
Onconova Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Onconova Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Onconova Therapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Onconova Therapeutics, Inc. - Pipeline Products Glance 11
Onconova Therapeutics, Inc. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
Onconova Therapeutics, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Onconova Therapeutics, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Onconova Therapeutics, Inc. - Drug Profiles 16
rigosertib sodium 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
briciclib sodium 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
recilisib sodium 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ON-012380 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ON-015640 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ON-044580 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ON-108600 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ON-1231320 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ON-123300 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ON-146040 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ON-24 Series 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ON-24160 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ON-108110 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ON-128060 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Onconova Therapeutics, Inc. - Pipeline Analysis 35
Onconova Therapeutics, Inc. - Pipeline Products by Target 35
Onconova Therapeutics, Inc. - Pipeline Products by Route of Administration 37
Onconova Therapeutics, Inc. - Pipeline Products by Molecule Type 38
Onconova Therapeutics, Inc. - Pipeline Products by Mechanism of Action 39
Onconova Therapeutics, Inc. - Recent Pipeline Updates 41
Onconova Therapeutics, Inc. - Dormant Projects 46
Onconova Therapeutics, Inc. - Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Onconova Therapeutics, Inc., Key Information 5
Onconova Therapeutics, Inc., Key Facts 5
Onconova Therapeutics, Inc. - Pipeline by Indication, 2014 7
Onconova Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9
Onconova Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
Onconova Therapeutics, Inc. - Phase III, 2014 11
Onconova Therapeutics, Inc. - Phase II, 2014 12
Onconova Therapeutics, Inc. - Phase I, 2014 13
Onconova Therapeutics, Inc. - Preclinical, 2014 14
Onconova Therapeutics, Inc. - Discovery, 2014 15
Onconova Therapeutics, Inc. - Pipeline by Target, 2014 36
Onconova Therapeutics, Inc. - Pipeline by Route of Administration, 2014 37
Onconova Therapeutics, Inc. - Pipeline by Molecule Type, 2014 38
Onconova Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 40
Onconova Therapeutics, Inc. - Recent Pipeline Updates, 2014 41
Onconova Therapeutics, Inc. - Dormant Developmental Projects,2014 46
Onconova Therapeutics, Inc., Other Locations 47